We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.73M
Cap. Flow
+$224M
Cap. Flow %
177.31%
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127

Top Buys

1
PG icon
Procter & Gamble
PG
+$3.82M
2
BMY icon
Bristol-Myers Squibb
BMY
+$2.47M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2M
4
ULTA icon
Ulta Beauty
ULTA
+$1.86M
5
MON
Monsanto Co
MON
+$1.82M

Top Sells

1
MDVN
MEDIVATION, INC.
MDVN
+$7.18M
2
BIIB icon
Biogen
BIIB
+$4.33M
3
CALM icon
Cal-Maine
CALM
+$3.64M
4
AAPL icon
Apple
AAPL
+$2.74M
5
ALR
Alere Inc
ALR
+$2.22M

Sector Composition

1 Healthcare 39.95%
2 Consumer Staples 5.72%
3 Consumer Discretionary 5.14%
4 Technology 3.35%
5 Materials 2.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCOM icon
451
CALL
Trip.com Group
TCOM
$27.5B
– –
-6,200
Closed -$2K
TCOM icon
452
Trip.com Group
TCOM
$27.5B
– –
-4,947
Closed -$204K
TCOM icon
453
PUT
Trip.com Group
TCOM
$27.5B
– –
-6,200
Closed -$43K
TNXP icon
454
CALL
Tonix Pharmaceuticals
TNXP
$189M
– –
0
– -$1K
TXN icon
455
PUT
Texas Instruments
TXN
$265B
– –
-7,100
Closed -$15K
YUM icon
456
Yum! Brands
YUM
$41.9B
– –
-1,669
Closed -$107K
CMRX
457
CALL
DELISTED
Chimerix, Inc.
CMRX
– –
-199,900
Closed -$27K
RVNC
458
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-11,577
Closed -$157K
LUMO
459
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-2,434
Closed -$242K
LUMO
460
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-2,433
Closed -$1.29M
ICPT
461
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-10,779
Closed -$1.7M
CYTO
462
CALL
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
0
– -$4K
CYTO
463
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-1
Closed -$205K
PRTK
464
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-10,000
Closed -$139K
OTIC
465
CALL
DELISTED
Otonomy, Inc.
OTIC
– –
-700
Closed -$1K
ALXN
466
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-8,673
Closed -$1.01M
ALXN
467
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-9,000
Closed -$756K
IMPV
468
DELISTED
Imperva, Inc.
IMPV
– –
-4,916
Closed -$211K
PNK
469
DELISTED
Pinnacle Entertainment Inc.
PNK
– –
-23,500
Closed -$260K
CXRX
470
CALL
DELISTED
Concordia International Corp. Common Stock
CXRX
– –
-17,400
Closed -$19K
CXRX
471
DELISTED
Concordia International Corp. Common Stock
CXRX
– –
-6,471
Closed -$81.1K
CASC
472
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-8,650
Closed -$1K
POT
473
PUT
DELISTED
Potash Corp Of Saskatchewan
POT
– –
-50,000
Closed -$35K
ALR
474
DELISTED
Alere Inc
ALR
– –
-53,163
Closed -$2.22M
ALR
475
PUT
DELISTED
Alere Inc
ALR
– –
-50,200
Closed -$442K
16 17 18
19
20

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2016 Portfolio in Review

As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.

  • FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
  • FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
  • FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
  • FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
  • FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
  • FT Options opened 153 new positions and closed 127 in Q3 2016.
  • FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.